In news: An anti-COVID-19 therapeutic application 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
About the drug-
- Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
- Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients.
- In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints.
- The drug comes in powder form in sachet, which is taken orally by dissolving it in water.
- It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production.
- Its selective accumulation in virally infected cells makes this drug unique.
- Drugs Controller General of India (DCGI) has granted permission for emergency use of 2-DG.